Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HC010 in advanced PD-L1 positive NSCLC
NCT07169552Phase 2Recruiting
- Start
- Dec 2025
- Primary completion
- Dec 2026
- Modality
- Antibody Conjugates, Trispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of HC010 in non-small cell lung cancer (NSCLC). Started Dec 2025; status: recruiting.
02
Drugs
HC010
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07169552.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07169552.